Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
iRhythm Holdings, Inc. files its annual report describing a specialized cardiac monitoring business built around its Zio wearable patch and ZEUS analytics software. The company delivers long-term continuous and mobile cardiac telemetry monitoring services mainly through Medicare-enrolled diagnostic testing facilities.
iRhythm highlights more than twelve million patient reports and nearly three billion hours of curated heartbeat data, a workforce of about 2,400 employees, and a market value of roughly $4.9 billion. The report emphasizes dependence on reimbursement, complex billing and regulatory oversight, strong competition, and expanding use of AI-driven diagnostics and international growth.
iRhythm Holdings reported strong growth for the fourth quarter and full year 2025. Fourth quarter revenue reached $208.9 million, up 27.1% from 2024, with gross margin at 70.9%. The company delivered net income of $5.6 million, its first quarter of positive GAAP net income.
For full year 2025, revenue rose 26.2% to $747.1 million, and gross margin improved to 70.6%. The annual GAAP net loss narrowed to $44.6 million from $113.3 million, and free cash flow was positive at $34.5 million, the first positive year in company history. Unrestricted cash, cash equivalents and marketable securities were $583.8 million at December 31, 2025.
For 2026, iRhythm guides to revenue of $870–$880 million and an adjusted EBITDA margin of 11.5%–12.5%, reflecting expectations for continued volume-led growth, margin expansion, and operating leverage.
Sands Capital Management, LLC and Frank M. Sands report beneficial ownership of 1,699,645 shares of iRhythm Holdings, Inc. common stock, representing 5.3% of the outstanding class. This percentage is based on 32,219,143 shares outstanding as of October 23, 2025, as disclosed in iRhythm’s Form 10-Q.
The shares are held in accounts of various Sands Capital clients, including institutions and individuals, and no single client holds more than 5% of the class. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of iRhythm.
iRhythm Holdings, Inc. received an amended Schedule 13G/A from Artisan-affiliated investment entities reporting their ownership of the company’s common stock. As of the reported date, these entities beneficially own 1,511,992 shares, representing 4.7% of the outstanding common stock, based on 32,219,143 shares outstanding as of October 23, 2025.
The Artisan entities report no sole voting or dispositive power over iRhythm shares, but shared voting power over 1,314,008 shares and shared dispositive power over 1,511,992 shares. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of iRhythm.
iRhythm Technologies, Inc. filed a Form 15 to end its own registration and reporting obligations after implementing a new holding company structure under Delaware law. In this transaction, iRhythm merged into a wholly owned subsidiary of iRhythm Holdings, Inc., with iRhythm surviving as a subsidiary.
At the effective time, each share of iRhythm common stock was automatically converted into one share of iRhythm Holdings common stock, with the same rights and preferences. The transaction is treated as a succession under Rule 12g-3(a), so iRhythm Holdings continues as the Exchange Act reporting company.
iRhythm Technologies, Inc. (IRTC) furnished an investor presentation as part of its shareholder engagement program. The presentation is included as Exhibit 99.1 to the report.
The materials in this disclosure are provided under Item 7.01 (Regulation FD) and are expressly stated as “furnished,” not “filed,” which means they are not subject to Section 18 liability and are not incorporated into other Securities Act or Exchange Act filings except by specific reference.
iRhythm Technologies (IRTC) reported an insider transaction by its President and CEO, who is also a Director. On 11/03/2025, the officer sold 14,059 shares of common stock at a price of $182.9367 per share.
The filing states the shares were sold to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units. Following the sale, the officer beneficially owns 164,979 shares, held directly.
iRhythm Technologies (IRTC) reported an insider transaction on Form 4. The company’s Chief Financial Officer sold 8,000 shares of common stock at $207.44 on 10/31/2025 pursuant to a Rule 10b5-1 trading plan established on November 14, 2024. Following the sale, the officer beneficially owns 26,470 shares directly and 100 shares indirectly through The Wilson Living Trust.